TheScreener
Fundamental and technical screening for 1,000 listed companies.
Use ⌘K to search stocks, screens, and features instantly.
AstraZeneca Pharma India Limited
ASTRAZENMid CapNSEBSE
Biotechnology & Drugs · Biotechnology & Drugs
₹6,951.50down 155.00down 2.18 percentas of 31 Aug 2026
Div yield 0.52%
Key metrics
- Market Cap
- 17,813.30 ₹ cr
- P/E
- —
- P/B
- —
- ROE
- —
- ROCE
- —
- Debt to Equity
- —
- Net Margin
- —
- Dividend Yield
- 0.52%
- Revenue Growth (YoY)
- —
Observations
Mechanical observations generated from stored data, not analysis or opinion. Each one names the threshold that produced it — the ROCE check below uses 20%, a fixed default rather than a value tailored to this company.
- Promoter holding 75.0% (pledge data not available).
ASTRAZEN
₹6,951.50down 2.18 percent
EOD Synced: 31 Aug 2026 18:30 ISTOverview & Live Price Chart
Executive Investment Verdict & Quality Synthesis
Autonomous V2Multi-dimensional quantitative synthesis across capital efficiency, forensic accounting, intrinsic valuation, and ownership governance.
Factual Quantitative Consensus
1. Capital Efficiency & MoatModerate Return
—ROCE
ROE: —·P/B: —x
2. Forensic Health & SolvencyData Pending
—Piotroski Score
Altman: — (No Data)
3. Valuation & DCF SpreadFairly Valued
—x PETrailing P/E
CMP: ₹6,951.5
4. Ownership & GovernanceClean Promoter Holding
75.00%Promoter Stake
Pledged: 0.0%·Inst: 8.69%
Institutional Factor Scores
QVGM Factor Grade Matrix
Institutional Multi-Factor Profile (QVGM)
Composite 0–100 percentile ranks normalized across all 500 universe constituents
Rank #23 of 35 in Biotechnology & DrugsQVGM 43/100
Quality (Q)50
ROE, ROCE, Margins & Cash Conversion
Value (V)48
P/E, P/B, EV/EBITDA vs Sector Benchmarks
Growth (G)50
3Y Sales & EPS Compounded Growth
Momentum (M)16
Relative Strength & Trend Position
TheScreener Radar™ 5-Pillar Quantitative Scorecard
Holistic quantitative radar evaluating fundamental quality, valuation multiples, balance sheet health, growth, and price momentum
Sector Rank:Rank #23 of 35 in Biotechnology & Drugs
Valuation
Moderate48/100
P/E Ratio:—
P/B Ratio:—
Dividend Yield:0.52%
P/E, P/B, EV/EBITDA & Dividend Yield relative to 5Y medians and sector
Growth
Moderate50/100
3Y Sales CAGR:—
3Y PAT CAGR:—
Quarterly YoY:+12.4%
3-Year Compounded Sales & Net Profit Growth trajectory
Profitability
Moderate50/100
ROE:—
ROCE:—
OPM %:—
Return on Equity (ROE), ROCE & Operating Margin efficiency
Solvency & Health
Moderate45/100
Piotroski F-Score:—
Altman Z-Score:—
Debt / Equity:0.00
Balance Sheet strength, Altman Z-Score & Piotroski F-Score checklist
Momentum
Weak16/100
1Y Return:—
RSI (14):54.2
From 52W High:—
1-Year Relative Strength vs NIFTY 500, RSI-14 & 52W High distance
Quantitative Drivers & Growth Analysis
52-week corridor, deep valuation multiples, compounded CAGR trajectory, and institutional flow shifts
52-Week Low₹6,951.50
From 52W High-29.26%
52-Week High₹9,827.50
Valuation MultiplesCash Flow & Yield
PEG Ratio—
Earnings Yield—
Price / FCF—
FCF Yield—
Payout Ratio—
Net-Net Ratio—
Solvency & SafetyPiotroski & Altman
Piotroski F-Score—
Altman Z-Score—
Graham Number—
1Y Flow & Margin ShiftsTrailing 12M
FII Stake:▼ 0.10%
DII Stake:▲ +0.35%
OPM Margin:—
Net Margin:—
Compounded Annual Growth Rate (CAGR Matrix)
Historical Fundamental Trajectory| Metric | QoQ Shift | YoY Shift | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|
| Revenue Growth | — | — | — | — | — |
| Net Profit Growth | — | — | — | — | — |
| EPS Growth | — | — | — | — | — |
Intrinsic Valuation Models & DCF Sensitivity
New to intrinsic valuation models? Learn how Discounted Cash Flow and Terminal Growth rates work.Read DCF Academy Guide →
Valuation history
P/E—current
ReportedComputed, approximate
P/B—current
ReportedComputed, approximate
EV/EBITDA is not shown — there is no verified source for it in our data feed, and estimating it would misrepresent an estimate as a reported figure.
| Date | P/E | P/B |
|---|---|---|
| 31 Aug 2026 | — | — |
Analyst Consensus, Price Targets & Forecasts
Analyst Ratings
No analyst consensus data available for this company.
Risk Profile & Volatility
Statistical return volatility classification · 31 Aug 2026
Moderate risk
Low RiskModerate RiskHigh Risk
Annualised Standard Deviation:24.33%
Price Target
No analyst target price estimates available for this company.
Forward Financial Forecasts & Consensus Estimates
Institutional broker consensus estimates and forward earnings trajectory
FY2027E6 Analysts
Mean Estimate
₹12.14
Low:—
High:—
FY2027E6 Analysts
Mean Estimate
₹12.77
Low:—
High:—
FY2027E6 Analysts
Mean Estimate
₹13.41
Low:—
High:—
FY2027E6 Analysts
Mean Estimate
₹14.05
Low:—
High:—
FY2028E6 Analysts
Mean Estimate
₹13.93
Low:—
High:—
FY2028E6 Analysts
Mean Estimate
₹14.66
Low:—
High:—
FY2028E6 Analysts
Mean Estimate
₹15.40
Low:—
High:—
FY2028E6 Analysts
Mean Estimate
₹16.13
Low:—
High:—
| Period / Fiscal Year | Consensus Mean | Bull Case (High) | Bear Case (Low) | Brokers |
|---|---|---|---|---|
| FY2027 Forecast | ₹12.14 | — | — | 6 |
| FY2027 Forecast | ₹12.77 | — | — | 6 |
| FY2027 Forecast | ₹13.41 | — | — | 6 |
| FY2027 Forecast | ₹14.05 | — | — | 6 |
| FY2028 Forecast | ₹13.93 | — | — | 6 |
| FY2028 Forecast | ₹14.66 | — | — | 6 |
| FY2028 Forecast | ₹15.40 | — | — | 6 |
| FY2028 Forecast | ₹16.13 | — | — | 6 |
Third-party broker forecasts compiled from institutional research houses, not IndiScreener's proprietary estimates. Provided strictly for analytical benchmarking and does not constitute investment advice.
Forensic Accounting Audit & Solvency Risk
Forensic Accounting & Health Audit
Piotroski F-Score, Altman Z-Score Distress Model & Beneish Earnings Manipulation Checks
Piotroski F-Score—
● Insufficient Data
Altman Z-Score—
● No Data
Beneish M-Score—
● Insufficient Data
Learn how Piotroski F-Score (9 criteria) and Altman Z-Score detect earnings manipulation and bankruptcy risk.Read Forensic Guide →
10-Year Financial Statements & DuPont ROE
Financial Statements
consolidated · amounts in ₹ Crores
No annual financial data has been ingested for this company yet.
DuPont ROE Decomposition
DuPont analysis requires complete net margin, asset turnover, and equity multiplier metrics for the latest fiscal period. At least one of those hasn't been ingested yet for this company.
Explore the 3-Stage DuPont Formula: Net Margin × Asset Turnover × Leverage Multiplier.Read DuPont Guide →
Corporate Actions, Dividends & Capital Changes
Chronological Corporate Actions Registry
Historical stock splits, bonus shares, rights issues, and corporate schemes
| Year | Execution Date | Action Type | Ratio / Term |
|---|---|---|---|
| 2026 | 31 Jul 2026 | dividend | 1800% |
| 2025 | 18 Jul 2025 | dividend | 1600% |
| 2024 | 05 Jul 2024 | dividend | 1200% |
| 2023 | 14 Jul 2023 | dividend | 800% |
| 2022 | 08 Jul 2022 | dividend | 400% |
| 2021 | 20 Aug 2021 | dividend | 100% |
| 2020 | 21 Aug 2020 | dividend | 100% |
| 2019 | 21 Aug 2019 | dividend | 50% |
| 21 Aug 2019 | dividend | 50% | |
| 2012 | 11 Jul 2012 | dividend | 175% |
| 2011 | 09 Jul 2011 | dividend | 500% |
| 2010 | 08 May 2010 | dividend | 500% |
| 2009 | 05 May 2009 | dividend | 750% |
| 2008 | 16 Apr 2008 | dividend | 750% |
| 2007 | 24 Mar 2007 | dividend | 600% |
| 2006 | 22 Jun 2006 | split | 2:10 |
| 14 Apr 2006 | dividend | 200% |
Dividend Intelligence & Capital Return History
Historical cash payout track record across 6 dividend distributions
Latest Year DPS:₹36.00
Yield on CMP:0.52%
3Y Dividend CAGR:+31.0%
Annual Dividend Payout Progression (Per Share)Total Cumulative DPS: ₹118.00
₹36.0
2026
₹32.0
2025
₹24.0
2024
₹16.0
2023
₹8.0
2022
₹2.0
2021
| Ex-Date | Amount (Per Share) | Dividend Type |
|---|---|---|
| 31 Jul 2026 | ₹36.00 | Final |
| 18 Jul 2025 | ₹32.00 | Final |
| 05 Jul 2024 | ₹24.00 | Final |
| 14 Jul 2023 | ₹16.00 | Final |
| 07 Jul 2022 | ₹8.00 | Final |
| 18 Aug 2021 | ₹2.00 | Interim |
Industry Peer Group & Valuation Spread
Compare valuation multiples and market cap relative to sector competitors
Biotechnology & DrugsCompare Peers in Studio
Market Cap17,813.30 ₹ cr
Beats 100% of 9 industry peers · median 821.74 ₹ cr
Dividend Yield0.52%
Beats 17% of 6 industry peers · median 1.65%
| Company | Market Cap ▼ | P/E | P/B |
|---|---|---|---|
Alembic LimitedALEMBICLTD | ₹2,540.32 | 8.09 | 1.05 |
Amrutanjan Health Care LimitedAMRUTANJAN | ₹1,491.63 | 25.67 | 4.02 |
Bajaj Healthcare LimitedBAJAJHCARE | ₹1,129.36 | 47.93 | 2.03 |
| ₹829.17 | 26.55 | 3.67 | |
Anuh Pharma LimitedANUHPHR | ₹821.74 | 20.41 | 2.38 |
Peers are chosen strictly by industry classification. A classification doesn't always describe what a company actually competes in, but gives an objective starting point across the universe.
Regulatory Filings & Market Intelligence
Corporate Document & Filings Vault
No statutory exchange announcements or PDF filings have been recorded for ASTRAZEN yet.
News
No news has been ingested for this company yet.
For informational and educational purposes only. Not investment advice. Data may be delayed or incomplete. Consult a SEBI-registered investment adviser before making investment decisions.